<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207879</url>
  </required_header>
  <id_info>
    <org_study_id>YD_20190301</org_study_id>
    <nct_id>NCT04207879</nct_id>
  </id_info>
  <brief_title>Modified Atkins Diet for Overweight and Obesity</brief_title>
  <official_title>Longitudinal Profiling of Gut Microbiome in Overweight or Obese Participants on a Modified Atkins Diet: a Prospective Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Westlake University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hebei Medical University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate dynamic changes in biochemical metabolism, gut
      microbiome and its metabolites among overweight and obese participants while they are on a
      modified Atkins Diets.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The mechanisms of obesity are complex, involved in genes, environment, life style, and
      systemic and adipose tissue inflammation. Dysbiosis of gut microbiome is considered to make a
      difference in obesity. On the other hand, both long-term and short-term dietary interventions
      can induce changes in the body composition and structure and function of gut microbiome.
      However, it is not really clear how gut microbiome changes along with weight loss in
      overweight or obese.

      In the present study, investigators aim to characterize the gut microbiome among overweight
      or obese participants on a modified Atkins diets. The stool and blood samples were collected
      by an interval of every 5% and 10% of weight loss, respectively. Data collecting mainly
      covers: 1) body composition analysis ; 2) obesity related biochemical metabolism; 3)
      measurement of gut microbiome using metagenome and 16S rRNA sequencing techniques; 4)
      metabolomics of serum and gut microbiome; 5) measurement of physical activity and diets using
      questionnaires.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">February 1, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Dynamic changes of gut microbiome</measure>
    <time_frame>36 months</time_frame>
    <description>The stool sample will be collected by an interval of each 5% weight loss that participants experienced. Fecal microbiota will be analyzed by 16S rRNA gene sequencing technique.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dynamic changes in faecal metabolomics</measure>
    <time_frame>36 months</time_frame>
    <description>For participants achieving each 10% weight loss, targeting metabonomics will be applied to identify the abundances of faecal metabolites (e.g. short-chain fatty acids, amino acids and carbohyrates) using validated mass spectrometry methods.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of body mass index</measure>
    <time_frame>36 months</time_frame>
    <description>Weight and height will be combined to report BMI in kg/m^2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of body fat</measure>
    <time_frame>36 months</time_frame>
    <description>As a body composition parameter, body fat will be analyzed by body composition automatic analyzer for each participant every 10-20 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of muscle mass</measure>
    <time_frame>36 months</time_frame>
    <description>Muscle mass will be analyzed by body composition automatic analyzer for each participant every 10-20 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of blood lipids</measure>
    <time_frame>36 months</time_frame>
    <description>For participants achieving each 10% weight loss, intravenous serum will be collected and the parameters which can reflect the lipids metalism (such as triglyceride, total cholesterol, low density lipoprotein cholesterol, high density lipoprotein cholesterol ) will be measured by automatic biochemical analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of fasting blood glucose</measure>
    <time_frame>36 months</time_frame>
    <description>For participants achieving each 10% weight loss, intravenous serum will be collected and fasting blood glucose will be measured by automatic biochemical analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of homocysteine</measure>
    <time_frame>36 months</time_frame>
    <description>For participants achieving each 10% weight loss, intravenous serum will be collected and homocysteine will be measured by automatic biochemical analyzer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dynamic changes of blood pressure</measure>
    <time_frame>36 months</time_frame>
    <description>For participants achieving each 10% weight loss, blood pressure will be measured by the standard electronic sphygmomanometer.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Overweight or Obesity</condition>
  <arm_group>
    <arm_group_label>weight loss group</arm_group_label>
    <description>Dynamic changes in body composition, biochemical metabolomics and gut microbiome will be reported among overweight and obese patients.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood, urine, and feces
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study is conducted in Shijiazhuang, a city in Northen China. Eligible participants are
        residents in this area and aged 18-55 years old, who are on a modified Atkins diet aiming
        to lose weight.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18-55 years old;

          2. BMI &gt; 23.9kg/m2;

          3. being willing and able to receive guidelines to a modified Atkins diet;

          4. signed informed consent.

        Exclusion Criteria:

          1. patients with serious physical and mental diseases (including cardiovascular and
             cerebrovascular diseases, liver and kidney diseases, respiratory diseases
             gastrointestinal diseases, mental diseases, etc.);

          2. patients with malignant tumor;

          3. pregnant and lactating women;

          4. those with recent relocation plans.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hai-Ling Di, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hebei Medical University Third Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dan Yu, PhD</last_name>
    <phone>86-0311-88602667</phone>
    <email>yudan20122013@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuan-Qing Fu, PhD</last_name>
    <phone>86-0571-85270183</phone>
    <email>fuyuanqing@westlake.edu.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hebei Medical University Third Hospital</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <zip>050051</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Lin BY, Lin WD, Huang CK, Hsin MC, Lin WY, Pryor AD. Changes of gut microbiota between different weight reduction programs. Surg Obes Relat Dis. 2019 May;15(5):749-758. doi: 10.1016/j.soard.2019.01.026. Epub 2019 Jan 31.</citation>
    <PMID>30935838</PMID>
  </reference>
  <reference>
    <citation>Frost F, Storck LJ, Kacprowski T, Gärtner S, Rühlemann M, Bang C, Franke A, Völker U, Aghdassi AA, Steveling A, Mayerle J, Weiss FU, Homuth G, Lerch MM. A structured weight loss program increases gut microbiota phylogenetic diversity and reduces levels of Collinsella in obese type 2 diabetics: A pilot study. PLoS One. 2019 Jul 18;14(7):e0219489. doi: 10.1371/journal.pone.0219489. eCollection 2019.</citation>
    <PMID>31318902</PMID>
  </reference>
  <reference>
    <citation>Heianza Y, Sun D, Smith SR, Bray GA, Sacks FM, Qi L. Changes in Gut Microbiota-Related Metabolites and Long-term Successful Weight Loss in Response to Weight-Loss Diets: The POUNDS Lost Trial. Diabetes Care. 2018 Mar;41(3):413-419. doi: 10.2337/dc17-2108. Epub 2018 Jan 5.</citation>
    <PMID>29305401</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 4, 2019</study_first_submitted>
  <study_first_submitted_qc>December 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 23, 2019</study_first_posted>
  <last_update_submitted>January 9, 2020</last_update_submitted>
  <last_update_submitted_qc>January 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Third Hospital</investigator_affiliation>
    <investigator_full_name>Dan Yu, PhD</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>modified Atkins Diet</keyword>
  <keyword>Overweight</keyword>
  <keyword>Obesity</keyword>
  <keyword>Gut Microbiome</keyword>
  <keyword>Body composition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The data might be made available 24 months after completion of the study. Requests for access to the study data can be submitted via email to the principal investigator yudan20122013@163.com, and proposals are required to be attached for approval.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>24 months after completion of the study</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers engaged in rigorous, independent scientific research; Requests for access to the study data should be submitted via email to the principal investigator yudan20122013@163.com, and proposals are required to be attached for approval.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

